At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 310 enrolled
Drug / intervention
NYX-2925 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
In Brief
A Phase 2 clinical trial evaluating NYX-2925 and Placebo for Fibromyalgia. Completed, enrolled 310 participants across 42 sites.
Detailed Summary
To evaluate the efficacy of NYX-2925 versus placebo for the treatment of fibromyalgia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesUnited States
CollaboratorsWorldwide Clinical Trials
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartNov 2019
Primary CompletionJun 2022
TodayJul 2026
First PostedNov 1, 2019
Enrollment StartNov 12, 2019
Primary CompletionJun 16, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.7 years ago
Interventions
NYX-2925drug
NYX-2925 administered orally
Placebodrug
Placebo administered orally